Mark Davis Discusses Early Clinical Trial Results
In a Watson lecture on May 14, Mark Davis, Caltech's Schlinger Professor of Chemical Engineering and a member of the experimental therapeutics program at the City of Hope's Comprehensive Cancer Center, explained how nanoparticle medicines, or nanomedicines, have the potential to change the way cancer is treated. To demonstrate some of the distinguishing features of nanomedicine therapeutics for cancer, Davis presented results from early human clinical trials. Davis is also an NSBCC co-investigator. You may view his presentation by accessing the links found here: http://today.caltech.edu/theater/item?story%5fid=29604 .